Michael D Lynch


Associate Professor in the Department of Biomedical Engineering

Appointments and Affiliations

  • Associate Professor in the Department of Biomedical Engineering
  • Associate Professor in Chemistry
  • Faculty Fellow in The Energy Initiative
  • Associate of the Duke Initiative for Science & Society

Contact Information


  • M.D. University of Colorado School of Medicine, 2007
  • Ph.D. University of Colorado - Boulder, 2005

Research Interests

Focused on genetically engineering microbes to shut off their growth circuits and turn on new pathways to produce different compounds—improving production of biofuels, pharmacological molecules and industrial chemicals.

Awards, Honors, and Distinctions

    Courses Taught

    • BME 490L: Special Topics in Biomedical Engineering Design (DR)
    • BME 590L: Special Topics with Lab
    • BME 790L: Advanced Topics with the Lab for Graduate Students in Biomedical Engineering
    • BME 791: Graduate Independent Study
    • BME 792: Continuation of Graduate Independent Study
    • EGR 393: Research Projects in Engineering

    In the News

    Representative Publications

    • Yang, T; Ye, Z; Lynch, MD, "Multiagent" Screening Improves Directed Enzyme Evolution by Identifying Epistatic Mutations., Acs Synthetic Biology, vol 11 no. 5 (2022), pp. 1971-1983 [10.1021/acssynbio.2c00136] [abs].
    • Decker, JS; Menacho-Melgar, R; Lynch, MD, Integrated autolysis, DNA hydrolysis and precipitation enables an improved bioprocess for Q-Griffithsin, a broad-spectrum antiviral and clinical-stage anti-COVID-19 candidate., Biochemical Engineering Journal, vol 181 (2022) [10.1016/j.bej.2022.108403] [abs].
    • Moreb, EA; Lynch, MD, A Meta-Analysis of gRNA Library Screens Enables an Improved Understanding of the Impact of gRNA Folding and Structural Stability on CRISPR-Cas9 Activity., The Crispr Journal, vol 5 no. 1 (2022), pp. 146-154 [10.1089/crispr.2021.0084] [abs].
    • Decker, JS; Menacho-Melgar, R; Lynch, MD, Integrated Autolysis, DNA Hydrolysis and Precipitation Enables an Improved Bioprocess for Q-Griffithsin, a Broad-Spectrum Antiviral and Clinical-Stage anti-COVID-19 Candidate., Biorxiv (2022) [10.1101/2021.12.30.474602] [abs].
    • Hennigan, JN; Lynch, MD, The past, present, and future of enzyme-based therapies., Drug Discovery Today, vol 27 no. 1 (2022), pp. 117-133 [10.1016/j.drudis.2021.09.004] [abs].